Venture
Iambic Therapeutics, Inc.
Latest Form D 2026-09-09- CIK 1997038
- State CA
- Biotechnology
- 5 Form D offerings since 2023-10-12
- Total sold
- $335M
- across 5 offerings
- Rounds
- 5
- Form D offerings since 2023-10-12
- Latest round
- $66M
- 2026-09-09 · 021-596810
- Investors
- 16
- on the latest round
Connected
named in its Form D filingsOfferings · since 2023-10-125 Form D offeringsExemptions506(b)People · Item 3Thomas Miller + 12 moreInvestors · dashboard2 inferred investors
Iambic Therapeutics, Inc.CIK 1997038
Round timeline
amount sold · by first filed2026-09-09 · $66M
- 2023-10-12$103M021-494624
- 2024-04-25$38.4M021-511607
- 2025-11-21$99.3M021-564708
- 2026-04-08$27.8M021-579622
- 2026-09-09$66M021-596810
Hover a dot or row, or tab through the dots · bars scaled to the largest round ($103M)
Form D offerings
One line per offering, amendments folded in, newest first
| File | First filed | Latest | Sought | Sold | Investors | Exemptions |
|---|---|---|---|---|---|---|
| 021-596810 | First filed2026-09-09 | Latest2026-09-09 | Sought$66.5M | Sold$66M | Investors16 | Exemptions506(b) |
| 021-579622 | First filed2026-04-08 | Latest2026-04-08 | Sought$50M | Sold$27.8M | Investors7 | Exemptions506(b) |
| 021-564708 | First filed2025-11-21 | Latest2025-11-21 | Sought$125M | Sold$99.3M | Investors22 | Exemptions506(b) |
| 021-511607 | First filed2024-04-25 | Latest2024-06-06 | Sought$50M | Sold$38.4M | Investors11 | Exemptions506(b) |
| 021-494624 | First filed2023-10-12 | Latest2023-10-12 | Sought$110M | Sold$103M | Investors18 | Exemptions506(b) |
Who backs Iambic Therapeutics, Inc. — 2 inferred investors — and every Form D as filedSee plans
People
Named in Item 3 of its latest Form D, filed 2026-09-09
| Name | Relationship |
|---|---|
| Thomas Miller | RelationshipExecutive Officer, Director |
| Fred Manby | RelationshipExecutive Officer, Director |
| Neil Josephson | RelationshipExecutive Officer |
| Michael Secora | RelationshipExecutive Officer |
| Jishnu Bhattacharjee | RelationshipDirector |
| Evan Rachlin | RelationshipDirector |
| R. Jacob Vogelstein | RelationshipDirector |
| Mary Tagliaferri | RelationshipDirector |
| William Rastetter | RelationshipDirector |
| Kurt von Emster | RelationshipDirector |
| Shalini Sharp | RelationshipDirector |
| Pete Olson | RelationshipExecutive Officer |
| Samit Hirawat | RelationshipDirector |
Facts
As its latest Form D states them
- Industry
- Biotechnology
- State
- California (CA)
- Exemptions
- Rule 506(b)
- First filed
- 2023-10-12
- Latest filing
- 2026-09-09
Who backs Iambic Therapeutics, Inc.
Form D names a startup's officers and directors, not its investors. The dashboard infers them — the venture funds whose own filings and people overlap this company's rounds — and lays every Form D and amendment it filed beside the totals above.
- Inferred investors — the funds and firms behind it, from co-filings and shared people
- Every Form D and amendment as filed, with what each one stated
- Its rounds in sequence: the gap between them and whether they grew
- Everyone its filings name, linked to their other companies, with its addresses and phone numbers
Part of the Venture plan — $140/mo at launch pricing ($350 list)
See plansExternal link: SEC Filings ↗